OwnershipPublicly listed · Nasdaq: LGVNSEC EDGAR company record and tickers file (Nasdaq: LGVN) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: LGVN, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
13developments published
—US federal obligations on record
9private-offering notices since 2019
Oct 26, 2026latest development
Timeline
- Oct 26, 2026 · Company announcement
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company-reported - Oct 7, 2026 · Leadership change
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Regulatory filing - Sep 16, 2026 · Company announcement
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company-reported - Aug 20, 2026 · Company announcement
Longeveron Announces 1-for-10 Reverse Stock Split
Company-reported - Aug 17, 2026 · Leadership change
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Company-reported - Aug 12, 2026 · Reported results
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Company-reported - Jul 8, 2026 · Leadership change
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Regulatory filing - Jul 8, 2026 · Leadership change
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Regulatory filing - Jun 30, 2026 · Leadership change
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Company-reported - Jun 1, 2026 · Leadership change
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Regulatory filing - May 13, 2026 · Reported results
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Company-reported - May 8, 2026 · Company announcement
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome
Company-reported - Mar 25, 2026 · Private financing (Form D)
Longeveron reports $15.9 million of securities sold in a private offering
Regulatory filing
Profile
- Legal name
- Longeveron Inc.
- Listing
- Nasdaq LGVN
- SEC filer
- CIK 0001721484 ↗
- SEC industry code
- Pharmaceutical Preparations
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Longeveron
Anything new from Longeveron lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestPrivate offerings reported to the SEC (Form D)
A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.
| Filed | Form | Amount sold | Offering size | First sale | Investors | Exemption | Record |
|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | D | $15.9 million | $33.5 million | Mar 11, 2026 | 7 | Rule 506(b) | SEC ↗ |
| Jul 23, 2024 | D | $0.00 | $9.5 million | Jul 19, 2024 | 3 | Rule 506(b) | SEC ↗ |
| Jun 25, 2024 | D | $0.00 | $9.4 million | Jun 18, 2024 | 3 | Rule 506(b) | SEC ↗ |
| Apr 25, 2024 | D | $0.00 | $12.4 million | Apr 18, 2024 | 3 | Rule 506(b) | SEC ↗ |
| Jan 8, 2024 | D | $0.00 | $2.6 million | Dec 22, 2023 | 1 | Rule 506(b) | SEC ↗ |
| Oct 24, 2023 | D | $0.00 | $8.4 million | Oct 13, 2023 | 1 | Rule 506(b) | SEC ↗ |
| Dec 13, 2021 | D | $20.5 million | $20.5 million | Dec 3, 2021 | 20 | Rule 506(b) | SEC ↗ |
| Feb 6, 2020 | D/A | $954,970 | $25.0 million | Oct 20, 2017 | 5 | Rule 506(b) | SEC ↗ |
| Feb 6, 2020 | D | $100,000 | $25.0 million | Jan 22, 2020 | 1 | Rule 506(b) | SEC ↗ |